Head-to-head evidence
Dalcetrapib (RO4607381) vs Obicetrapib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: CETP · full Atherosclerotic Cardiovascular Disease pipeline
Dalcetrapib (RO4607381)
Developed by Roche
NCT00655473 · Phase 2 · completed
The study randomized 130 participants to dalcetrapib or placebo and masked both participants and investigators. Its primary outcomes were surrogate MRI plaque measures rather than clinical events, and the registry does not state whether either comparison was statistically significant; the reported results were not clearly consistent across the two primary measures.
Next expected readout: August 2027 · NCT05918861 (registry estimate)
Obicetrapib
Developed by NewAmsterdam Pharma
NCT05142722 · Phase 3 · completed
Participants were randomized 2:1 to obicetrapib or placebo and the trial was quadruple-blinded, with 2,530 participants enrolled. The primary LDL-cholesterol endpoint was met, with a statistically significant treatment difference, but LDL cholesterol is a surrogate laboratory endpoint rather than a hard clinical or endoscopic measure, supporting a moderate grade.
Next expected readout: November 2026 · NCT06496243 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dalcetrapib (RO4607381)'s landscape · Obicetrapib's landscape